This is an open-label, prospective, multi-center, patient registry in Chinese Hemophilia A and B patients treated with anti-hemophilic coagulation factor replacement therapy.

Inclusion Criteria：

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:

1. Hemophilia A and Hemophilia B patient diagnosed;
2. Taking anti-hemophilic coagulation factor replacement therapy during the 2 year registry period.

Exclusion Criteria:

1. Unwilling or unable to follow the terms of the protocol.

Diagnosed Hemophilia A and Hemophilia B patient with anti-hemophilic coagulation factor replacement therapy will be selected.